NeurAxis, Inc. (NRXS) reported fourth-quarter 2025 revenues of $968,000, up 27% year-over-year, driven by a 35% increase in unit deliveries. This marks the sixth consecutive quarter of double-digit growth for the company. However, NeurAxis faced a net loss of $1.7 million, an increase from $1.4 million in the prior-year quarter, primarily due to elevated selling, general and administrative expenses, which rose 20% to $2.5 million.
For the full fiscal year, revenues grew by 32.9% to $3.6 million, while the net loss narrowed to $7.8 million from $8.2 million. The company expanded its coverage to over 100 million lives through partnerships with major insurers and emphasized the significance of a new Category I CPT code introduced on January 1, 2026, which facilitates therapy reimbursement.
Looking forward, management expects continued revenue growth through expanded insurance coverage and strategic investments in sales and marketing. NeurAxis has also secured a Federal Supply Schedule contract to provide services to nearly 7 million patients in the U.S. Department of Veterans Affairs healthcare system.
